drugset / Trial / NCT02127970

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02127970

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected Gram-positive acute bacterial skin and skin structure infections (ABSSSI) at 48 -72 hours after initiation of treatment.

Timeline

Start
2014-04-18
Primary completion
2015-03-11
Completion
2015-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalbavancin Other / unclassified 375 mg Intravenous
Subject Dalbavancin Other / unclassified 500 mg Intravenous
Subject Dalbavancin Other / unclassified 1000 mg Intravenous
Subject Dalbavancin Other / unclassified 1500 mg Intravenous